Trial Profile

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clofutriben (Primary) ; Cortisone
Indications Adrenal gland disorders; Cushing syndrome; Diabetic neuropathies; Obesity; Polymyalgia rheumatica
Focus Pharmacokinetics
Sponsors Sparrow Pharmaceuticals

Most Recent Events

15 Jun 2024 Interim Results assessing how SPI-62 alters prednisolone (PSL) efficacy and side effects in patients with PMR, presented at the 25th Annual Congress of the European League Against Rheumatism
18 Apr 2024 Status changed from active, no longer recruiting to completed.
15 Feb 2023 Planned End Date changed from 8 Jul 2022 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com